ARMARON BIO
Armaron Bio is a life sciences start-up company discovering and developing proprietary molecules to prevent heart failure, diabetes and other serious diseases. Its lead program is in clinical development and is currently undergoing a Proof of Concept Phase II trial in heart failure.
ARMARON BIO
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2003-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.armaronbio.com
Status:
Closed
Contact:
+61 3 9652 2121
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Apteeus
APTEEUS is a clinical stage biotech company
Aurum Healthcare
Aurum Healthcare is a clinical-stage biotechnology company.
Bionevia
BioNevia LLC is a clinical stage biotechnology company.
C3J Therapeutics
C3J Therapeutics is a clinical-stage biotechnology company.
GENERI BIOTECH
GENERI BIOTECH is an EU-located biotechnological company.
Iaso BioMed
Iaso BioMed is a developmental stage biotechnology company
KBP Biosciences
A multinational clinical stage biotechnology company.
Patrys
Patrys is a clinical-stage biotechnology company focused on therapies for human cancers.
Tychan
Tychan is a clinical-stage biotechnology company.
Current Employees Featured
More informations about "Armaron Bio"
Armaron Bio - Crunchbase Company Profile & Funding
Armaron Bio is a life sciences start-up company discovering and developing proprietary molecules to prevent heart failure, diabetes and other serious diseases. Its lead program is in clinical …See details»
Armaron Bio Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Armaron Bio. Use the PitchBook Platform to explore the full profile.See details»
Armaron Bio Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Armaron Bio Ltd. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, Technology Platform:Small molecule drug, Drug:Flavonol.See details»
Armaron Bio Pty Ltd: Contact Details and Business Profile
Armaron Bio is a life sciences start-up company based in Melbourne. Armaron Bio is developing proprietary lead cardioprotectant and neuroprotectant small molecules to reduce tissue …See details»
Armaron Bio - Overview, News & Similar companies - ZoomInfo
Armaron Bio is a life sciences start-up company based in Melbourne. Armaron Bio is developing proprietary lead cardioprotectant and neuroprotectant small molecules to reduce tissue …See details»
Armaron Bio - Company Profile - Tracxn
Nov 4, 2024 · Armaron Bio develops small molecule therapeutics for cardiovasular diseases. Its lead candidate targets muscle loss associated caused by myocardial infarctions by preventing …See details»
Armaron Bio - Company, Australia - SWFI - dev.swfinstitute.org
Armaron Bio is a Company located in Australia, Australia and Pacific, and was founded in 2004.See details»
Armaron Bio - Crunchbase
Armaron Bio is a clinical stage biotechnology company. Start Free Trial . Chrome ExtensionSee details»
Organization | Armaron Bio Pty Ltd - CDEK
Armaron Bio Pty Ltd Report issue For profit Phase 2 Founded: Melbourne Australia (2003)See details»
Armaron Bio - Contacts, Employees, Board Members, Advisors
Armaron Bio has 2 current employee profiles, including Chief Executive Officer Grant McLachlan. Armaron Bio is a clinical stage biotechnology company.See details»
Armaron Bio starts Phase 2 trial for novel lead candidate drug for ...
Armaron Bio, a Melbourne-based drug development company focused on heart failure and other diseases, is pleased to announce that it has begun its Phase II clinical trial for NP202, its novel …See details»
A heart failure drug that reduces scar tissue
Melbourne-based drug development company Armaron Bio has begun its Phase II clinical trial for NP202, its lead candidate drug for heart failure. Each year, around 54,000 Australians suffer a …See details»
Drug trial to reduce scarring after heart scare - The University of ...
Dec 1, 2015 · Developed by Melbourne-based pharmaceutical company Armaron Bio, it will be administered to patients in the days immediately following their heart attack. "After a heart …See details»
Flavonol - Drug Targets, Indications, Patents - Synapse - Patsnap
Flavonol: a p38 MAPK inhibitors Drug, Initially developed by Armaron Bio Ltd., Now, its global highest R&D status is Pending, Mechanism: p38 MAPK inhibitors(P38 mitogen-activated …See details»
Armaron Bio - Company, Australia - SWFI - Sovereign Wealth Fund …
Armaron Bio is a Company located in Australia, Australia and Pacific, and was founded in 2004.See details»
NP202 in ST Elevation Myocardial Infarction - ICH GCP
Sep 7, 2015 · NP202 is an experimental drug being developed by Armaron Bio Pty Ltd for potential use as a treatment for people after they have had a heart attack (MI).See details»
NP 202 - Armaron Biosciences - AdisInsight - Springer
If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with username/password or try to …See details»
NP202-002 protocol - ANZCTR
Armaron Bio Pty Ltd (previously NeuProtect Pty Ltd) has developed a novel compound, NP202, which has been shown reduce ventricular arrhythmias in sheep by inducing ischaemia and …See details»
The Bio Revolution: Innovations transforming economies, …
May 13, 2020 · Advances in biological science could transform economies and societies, helping to tackle global challenges from climate change to pandemics. A confluence of advances in …See details»
Life Science Contract Research Organization | Pharmaron
Pharmaron is a premier life science service provider offering comprehensive research, development, and manufacturing service capabilities throughout the drug discovery, …See details»